Cysteine-rich 61, a member of the CCN family, as a factor involved in the pathogenesis of proliferative diabetic retinopathy

Investigative Ophthalmology and Visual Science

Volumn 50, Issue 7, 2009, Pages 3447-3455

  You, Jian Jang ^a   Yang, Chang Hao ^b   Chen, Muh Shy ^b   Yang, Chung May ^b  

^a KEELUNG HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE RICH PROTEIN 61; MESSENGER RNA; MONOCLONAL ANTIBODY; OXYGEN; STREPTOZOCIN; VASCULOTROPIN; ANGIOGENIC FACTOR; DNA; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE MODEL; ENDOTHELIUM CELL; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN INTERACTION; RAT; RETINA NEOVASCULARIZATION; STREPTOZOCIN DIABETES; VITREOUS BODY; ANIMAL; ANOXIA; BIOSYNTHESIS; C57BL MOUSE; CAPILLARY; CELL MOTION; CHEMOLUMINESCENCE; CULTURE TECHNIQUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION; GENETICS; HUMAN; MACACA; METABOLISM; NEWBORN; PATHOLOGY; PHYSIOLOGY; RETINA BLOOD VESSEL; RETROLENTAL FIBROPLASIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; WISTAR RAT;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANOXIA; BLOTTING, WESTERN; CAPILLARIES; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL PROLIFERATION; CHEMILUMINESCENT MEASUREMENTS; CYSTEINE-RICH PROTEIN 61; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC RETINOPATHY; DNA; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HUMANS; INFANT, NEWBORN; MACACA MULATTA; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; RETINOPATHY OF PREMATURITY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 67649964636     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.08-2603     Document Type: Article

References (44)

1. Fong DS, Aiello L, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26(suppl):S99-S102.
2. Aiello LP, Gardner TW, King GL, et al. Diabetic retinopathy. Diabetes Care. 1998;21:143-156.
3. Duh EJ, Yang HS, Haller JA, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor: implications for ocular angiogenesis. Am J Ophthalmol. 2004; 137(4):668-674.
4. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118(4):445-450.
5. Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 2006;113(10):1695, e1-15.
6. Arevalo JF, Wu L, Sanchez JG, et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months followup. Eye. 2009;23(1):117-123.
7. Mason JO 3rd, Nixon PA, White MF. Intravitreal injection of bevacizumab (Avastin) as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol. 2006;142(4):685-688.
8. Spaide RF, Fisher YL. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 2006;26(3):275-278.
9. Arevalo JF, Maia M, Flynn H Jr, et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin(R)) in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol. 2008; 92:213-216.
10. Brigstock DR. Regulation of angiogenesis and endothelial cell function by connective tissue growth factor (CTGF) and cysteine-rich 61 (CYR61). Angiogenesis. 2002;5:153-165.
11. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet. 2004;363(9402):62-64.
12. Leask A, Abraham DJ. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci. 2006;119: 4803-4810.
13. Jay P, Berge-Lefranc JL, Marsollier C, Mejean C, Taviaux S, Berta P. The human growth factor-inducible immediate early gene, CYR61, maps to chromosome 1p. Oncogene. 1997;14:1753-1757.
14. Schutze N, Kunzi-Rapp K, Wagemanns R, Noth U, Jatzke S, Jakob F. Expression, purification, and functional testing of recombinant CYR61/CCN1. Protein Expr Purif. 2005;42:219-225.
15. Schutze N, Rucker N, Muller J, Adamski J, Jakob F. 5' Flanking sequence of the human immediate early responsive gene ccn1 (cyr61) and mapping of polymorphic CA repeat sequence motifs in the human ccn1 (cyr61) locus. Mol Pathol. 2001;54:170-175.
16. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin alpha(6)beta(1) and cell surface heparan sulfate proteoglycans. Endocrinology. 2002;143:1441-1450.
17. Lin MT, Chang CC, Chen ST, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem. 2004;279:24015-24023.
18. Hinton DR, Spee C, He S, et al. Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care. 2004;27:758-764.
19. Kuiper EJ, de Smet MD, van Meurs JC, et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol. 2006;124:1457-1462.
20. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci U S A. 1998;95: 6355-6360.
21. Kireeva ML, Mo FE, Yang GP, Lau LF. Cyr61, a product of a growth factor-inducible immediate-early gene, promotes cell proliferation, migration, and adhesion. Mol Cell Biol. 1996;16:1326-1334.
22. Hilfiker A, Hilfiker-Kleiner D, Fuchs M, et al. Expression of CYR61, an angiogenic immediate early gene, in arteriosclerosis and its regulation by angiotensin II. Circulation. 2002;106:254-260.
23. Boulton M, Gregor Z, McLeod D, et al. Intravitreal growth factors in proliferative diabetic retinopathy: correlation with neovascular activity and glycaemic management. Br J Ophthalmol. 1997;81:228-233.
24. Hirase K, Ikeda T, Sotozono C, Nishida K, Sawa H, Kinoshita S. Transforming growth factor beta2 in the vitreous in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:738-741.
25. Gately S, Twardowski P, Stack MS, et al. Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Res. 1996;56:4887-4890.
26. Fielder AR, Robinson J. Oxygen-induced retinopathy. Invest Ophthalmol Vis Sci. 1993;34:3-5.
27. Smith LE, Wesolowski E, McLellan A, et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci. 1994;35:101-111.
28. Nakayama H, Mitsuhashi T, Kuwajima S, et al. Immunochemical detection of advanced glycation end products in lens crystallins from streptozocin-induced diabetic rat. Diabetes. 1993;42:345-350.
29. Fataccioli V, Abergel V, Wingertsmann L, et al. Stimulation of angiogenesis by Cyr61 gene: a new therapeutic candidate. Hum Gene Ther. 2002;13:1461-1470.
30. Chen CC, Mo F, Lau LF. The angiogenic factor Cyr61 activities a genetic program for wound healing in human skin fibroblasts. J Biol Chem. 2001;276:47329-47337.
31. Kunz M, Moeller S, Koczan D, et al. Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells. J Biol Chem. 2003;278:45651-45660.
32. Hughes JM, Kuiper EJ, Klaassen I, et al. Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia. 2007; 50:1089-1098.
33. Miller JW, Adamis AP, Aiello LP. Vascular endothelial growth factor in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
34. Frank RN. Vascular endothelial growth factor: its role in retinal vascular proliferation. N Engl J Med. 1994;331:1519-1520.
35. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-792.
36. Strammiello R, Benini S, Manara MC, et al. Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells. Horm Metab Res. 2003;35:675-684.
37. Athanasopoulos AN, Schneider D, Keiper T, et al. Vascular endothelial growth factor (VEGF)-induced up-regulation of CCN1 in osteoblasts mediates proangiogenic activities in endothelial cells and promotes fracture healing. J Biol Chem. 2007;282:26746-26753.
38. Kuiper EJ, Hughes JM, Van Geest RJ, et al. Effect of VEGF-A on expression of profibrotic growth factor and extracellular matrix genes in the retina. Invest Ophthalmol Vis Sci. 2007;48:4267-4276.
39. Chen Y, Du XY. Functional properties and intracellular signaling of CCN1/Cyr61. J Cell Biochem. 2007;100:1337-1345.
40. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999;13:9-22.
41. Yu Y, Gao Yu, Wang H, et al. The matrix protein CCN1 (CYR61) promote proliferation, migration and tube formation of endothelial progenitor cells. Exp Cell Res. 2008:1-11.
42. Liu Haibo, Yang Ru, Timmer B, et al. Cysteine-rich protein 16 and connective tissue factor induce deadhesion and anoikis of retinal pericytes. Endocrinology. 2008;149:16666-16677.
43. Zhou D, Herrick DJ, Rosenbloom J, Chaqour B. Cyr61 mediates the expression of VEGF, αv-integrin, and α-actin genes through cytoskeletally based mechanotransduciton mechanisms in bladder smooth muscle cells. J Appl Physiol. 2005;98:2344-2354.
44. Chen N, Chen CC, Lau LF. Adhesion of human skin fibroblasts to Cyr61 is mediated through integrin alpha 6beta 1 and cell surface heparan sulfate proteoglycans. J Biol Chem. 2000;275:24953-24961.